Interlink provides Januvia pre-launch med ed

Share this article:
Interlink Healthcare Communications will provide pre-launch medical education for Merck's Januvia (sitagliptin), a DPP-4 inhibitor for treating type II diabetes. Januvia is expected to be decided on by the FDA in October.
Share this article:
You must be a registered member of MMM to post a comment.


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.